Taxotere
information and resources from the National Cancer Institute
Taxotere
(Other name for: docetaxel)Taxotere
(Other name for: docetaxel)
docetaxel Aventis Pharmaceutical Nov 27 2002
docetaxel
Accel. Approv. (clinical benefit subsequently established) Treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy.
Aventis Pharmaceutical May 14 1996
docetaxel
For locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
Aventis Pharmaceutical Dec 23 1999
docetaxel
For the treatment of locally advanced or metastatic breast cancer which has progressed during anthracycline-based treatment or relapsed during anthracycline-based adjuvant therapy.
Aventis Pharmaceutical Jun 22 1998
docetaxel
in combination with cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
Aventis Pharmaceutical Nov 27 2002
|
|
|
|
news articles
Taxotere Now Approved for Stomach Cancer Mar 31, 2006
ACS News Center, Drug maker sanofi-aventis says the US Food and Drug Administration has approved its drug docetaxel (sold as Taxotere) for people with advanced disease. ...
Sanofi-Aventis: Taxotere fighting to maintain blockbuster status Mar 29, 2006
Pharmaceutical Business Review Sanofi-Aventis has extended the patient population available to its blockbuster cancer drug Taxotere having won FDA approval for the drug as a treatment of ...
FDA Approves TAXOTERE® for stomach cancer Mar 25, 2006
Cancerfacts.com, The drug, Taxotere®, made by Sanofi-aventis was given a priority review by the FDA and was approved for use with a standard chemotherapy regimen to treat ...
Phase II Trial of Taxotere® and Xeloda® for Metastatic Gastric ... Mar 30, 2006
Cancer Consultants (press release), Annals of Oncology, treatment of metastatic adenocarcinoma of the stomach or gastroesophageal junction with the chemotherapy drugs Taxotere® (docetaxel) and ...
UPDATE 2-Sanofi's Taxotere wins backing for approval Mar 24, 2006
Reuters PARIS, March 24 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) has won backing for the use of its Taxotere treatment in advanced stomach cancer ...
Update 1-Sanofi's Taxotere gets FDA nod for stomach cancer Mar 23, 2006
Reuters NEW YORK, March 23 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) on Thursday said US regulators have approved its Taxotere cancer medicine for ...
Sanofi-Aventis Gets New Taxotere FDA OK Mar 23, 2006
Houston Chronicle, BRIDGEWATER, NJ — French drug maker Sanofi-Aventis SA said Thursday that the Food and Drug Administration approved its cancer drug Taxotere to treat patients ...
Taxotere® plus Gemzar® Provides AntiCancer Responses in ... Mar 29, 2006
Cancer Consultants (press release), According to an article recently published in the International Journal of Cancer, the combination consisting of chemotherapy agents Taxotere® (docetaxel) and ...
Sanofi's Taxotere wins US FDA approval for advanced stomach cancer ... Mar 23, 2006
Forbes PARIS (AFX) - Sanofi-Aventis SA said its blockbuster cancer drug Taxotere received approval from the US Food and Drug Administration for a supplemental new ...
Sanofi-Aventis says EU committee recommends Taxotere for stomach ... Mar 23, 2006
Forbes PARIS (AFX) - Sanofi-Aventis SA said a committee of the European Union's European Medicines Agency has recommended the cancer drug Taxotere for use in treating ...
Taxotere (Docetaxel) Receives US FDA Approval For Use In Advanced ... Mar 23, 2006
DG News ...that following a priority review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved Taxotere(R) (docetaxel ...
Taxotere OK'd for advanced stomach cancer Mar 23, 2006
United Press International BRIDGEWATER, NJ, March 23 (UPI) -- Sanofi-aventis said Thursday it has been cleared for US marketing of Taxotere for advanced stomach cancer. ...
Taxotere Receives US FDA Approval For Use In Advanced Stomach ... Mar 24, 2006
Playfuls.com, ...a priority review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection ...
Sanofi-aventis Receives FDA Approval For TAXOTERE Injection ... Mar 23, 2006
Trading Markets, Heralding good tidings for cancer patients, Sanofi-aventis (SNY | charts | news | Powerrating) on Thursday, announced that it's TAXOTERE Injection Concentrate ...
Sanofi-aventis Reveals US FDA Nod For TAXOTERE For Use In Advanced ... Mar 23, 2006
Trading Markets, ...(RTTNews) - Sanofi-aventis (SNY | charts | news | Powerrating) on Thursday said that the US FDA approved TAXOTERE Injection Concentrate in combination with ...
FDA Approvals: Aranesp, Taxotere, Leukine Mar 28, 2006
Medscape (subscription) On March 22, the FDA approved a new indication for docetaxel injection (Taxotere, made by Aventis Pharmaceuticals, Inc), allowing its use in combination with ...
TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... Mar 23, 2006
PR Newswire (press release), TAXOTERE(R)-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer BRIDGEWATER, NJ, March 23 /PRNewswire ...
TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... Mar 23, 2006
Yahoo! News (press release) ...a priority review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved TAXOTERE® (docetaxel) Injection ...
TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... Mar 23, 2006
PR Newswire (press release), ...that following a priority review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved TAXOTERE(R) (docetaxel ...
FDA APPROVES TAXOTERE(R) FOR THE TREATMENT OF PATIENTS WITH ... Mar 24, 2006
PR Newswire (press release), Taxotere(R)-based regimen is first treatment in more than a decade to demonstrate a survival advantage for patients with advanced stomach cancer, who have not ...
Taxotere Receives Positive Opinion from the Committee for ... Mar 24, 2006
PharmaLive.com (press release), ...for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval in Europe of TAXOTERE® (docetaxel) Injection ...
Taxotere® Approved for Advanced Gastric Cancer Mar 24, 2006
Cancer Consultants (press release), The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Taxotere® (docetaxel) for the treatment of advanced gastric cancer. ...
Taxotere®/Platinol®/Herceptin® Effective in Locally Advanced ... Mar 22, 2006
Cancer Consultants (press release), According to an early online article published in the Journal of Clinical Oncology, the treatment regimen consisting of Taxotere® (docetaxel), Platinol ...
Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... Mar 6, 2006
Cancer Consultants (press release), Researchers affiliated with the FinHer Study have reported that Taxotere® (docetaxel) is superior to Navelbine® (vinorelbine) when given in addition to 5-FU ...
(PRN) - FDA APPROVES TAXOTERE(R) FOR THE TREATMENT OF PATIENTS ... Mar 24, 2006
Bolsamania.com, ...(PRN) - The Hartford Expands Capabilities in Group Disability, Life, and Accident Coverage Offered to Physician Groups ... [+. PRN ...
FDA APPROVES TAXOTERE(R) FOR THE TREATMENT OF PATIENTS WITH ... Mar 24, 2006
PR Newswire (press release), THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED TAXOTERE(R) (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND 5-FLUOROURACIL FOR THE ...
MultiVu Video Feed: FDA Approves New Treatment For Patients With ... Mar 23, 2006
PR Newswire (press release), NEW YORK, March 23 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved TAXOTERE(R) (docetaxel) Injection Concentrate in combination with ...
Committee for Medicinal Products for Human Use Post-authorisation ... Mar 24, 2006
PharmaLive.com (press release), ...for Human Use (CHMP) adopted a positive opinion++ to recommend the variation to the terms of the marketing authorisation for the medicinal product Taxotere. ...
Business news in brief Mar 24, 2006
Philadelphia Inquirer, Sanofi-Aventis SA said its cancer drug Taxotere won federal regulatory approval for treating an advanced stage of the disease in the stomach. ...
FDA APPROVES NEW TREATMENT FOR PATIENTS WITH ADVANCED STOMACH ... Mar 23, 2006
PR Newswire (press release), The US Food and Drug Administration (FDA) has approved TAXOTERE® (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for the ...
Paris shares AFX market data at 11.10 am Mar 24, 2006
Forbes Sanofi-Aventis, up 0.95 eur or 1.23 pct at 78.10, after saying an EU committee has recommended Taxotere for stomach cancer use. ...
CMPH 20-23 March 2006 Initial Marketing Authorisation Applications ... Mar 25, 2006
Medical News Today (press release), Taxotere (docetaxel), from Aventis Pharma SA, to add the treatment of metastatic gastric adeno-carcinoma in combination with cisplatin and 5-fluorouracil. ...
Health Canada approves Xeloda(R) for adjuvant therapy in the ... Mar 29, 2006
CNW Telbec (Communiqués de presse), Canada for the treatment of advanced or metastatic breast cancer in 1998, metastatic colorectal cancer in 2000, and in combination with Taxotere for metastatic ...
Spectrum presents new satraplatin prostate cancer data Feb 28, 2006
Pharmaceutical Business Review Seven patients in the study had hormone-refractory prostate cancer (HRPC), and all of the HRPC patients had received Sanofi-Aventis' Taxotere (docetaxel), with ...
Taxol® and Paraplatin® Superior to Novantrone® for Hormone ... Mar 10, 2006
Cancer Consultants (press release), Novantrone alone has been replaced by Taxotere® (docetaxel)-based regimens for the chemotherapy treatment of hormone refractory prostate cancer. ...
Foreign Briefing Asia, Americas, Europe Mar 23, 2006
New York Times, Sanofi-Aventis said that regulators in the United States had approved its Taxotere cancer medicine for use in combination with chemotherapy to treat patients ...
Treatment “Holidays� Effective in Hormone-Refractory Prostate ... Mar 1, 2006
Cancer Consultants (press release), ...included a subgroup of 45 patients involved in a larger clinical trial referred to as the ASCENT trial in which treatment with Taxotere® (docetaxel) plus ...
Taxol® and Paraplatin® Superior to Novantrone® for Hormone ... Mar 10, 2006
Cancer Consultants (press release), More recently, however, Taxotere® (docetaxel)-based regimens have replaced Novantrone as initial chemotherapy regimens in the treatment of HRPC. ...
Patients Want To Know Results Of Their Clinical Trials Mar 26, 2006
Medical News Today (press release), The study by the TACT (Taxotere as Adjuvant ChemoTherapy) trial management group, questioned UK patients involved in clinical trials and asked if they would ...
Cell Genesys Reports Encouraging Follow-Up Survival Data From ... Feb 27, 2006
International News Service, ...to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel ...
Between 2010 and 2015 the Therapeutic Lung Cancer Drug Market is ... Mar 25, 2006
New Age Media Concepts (press release) Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventisi Taxotere (docetaxel), Bristol-Myers ...
Abraxis Oncology Names Joseph Hogan Vice President of US Sales and ... Mar 20, 2006
PharmaLive.com (press release), Prior to joining Berlex, he served in numerous leadership positions at Sanofi-Aventis, including that of US marketing director for Taxotere(R) where he played ...
GPC Biotech Reports Financial Results for Fiscal Year 2005 Mar 14, 2006
PR Newswire (press release), ...evaluating satraplatin plus Taxol(R) in patients with advanced non-small cell lung cancer * Start of Phase 1 trial evaluating satraplatin plus Taxotere(R) in ...
GVAX® Vaccine Promising for Hormone-Refractory Prostate Cancer Feb 28, 2006
Cancer Consultants (press release), These results compare favorably to the median survival of less than 19 months for the treatment of HRPC with Taxotere® (docetaxel)/prednisone, which is the ...
Cell Genesys Reports Encouraging Follow-Up Survival Data From ... Feb 27, 2006
Yahoo! News (press release) ...previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere® (docetaxel) chemotherapy ...
Spectrum Pharmaceuticals announces Presentation of New Satraplatin ... Feb 27, 2006
PR Newswire (press release), ...- New preclinical data on efficacy of satraplatin in prostate cancer cells and with Taxotere also presented - In December, a rolling submission of an NDA with ...
Pharmion Corporation Announces New Satraplatin Clinical Data From ... Feb 27, 2006
PR Newswire (press release), ...* New Preclinical Data on Efficacy of Satraplatin in Prostate Cancer Cells and With Taxotere(R) Also Presented BOULDER, Colo., Feb. ...
ASCO Prostate: Intermittent Chemotherapy Controls Androgen ... Feb 28, 2006
MedPage Today, The 56 patients were culled from 250 men who participated in the phase III randomized ASCENT trial, which compared Taxotere (docetaxel) plus a high-dose ...
Euroshares outlook - mixed as M&A excitement offsets Wall St ... Mar 23, 2006
Forbes Elsewhere in the healthcare sector, Sanofi-Aventis said its cancer drug Taxotere won US regulatory approval for treating an advanced stage of the disease in ...
Paris shares higher midday as Alcatel-Lucent merger talks lift ... Mar 24, 2006
Forbes Sanofi-Aventis was up 0.95 eur or 1.23 pct at 78.10, after saying an EU committee has recommended Taxotere for stomach cancer use. ...
BAE, Bayer, LSE, Sanofi, Siemens: European Equity Preview Mar 23, 2006
Bloomberg Sanofi-Aventis SA (SAN FP): The world's third-largest drugmaker said its cancer drug Taxotere won US regulatory approval for treating an advanced stage of the ...
Paris shares slightly higher late afternoon on Alcatel merger news Mar 24, 2006
Forbes Sanofi-Aventis was up 0.10 eur or 0.13 pct at 78.10, after saying a committee of the EU's European Medicines Agency has recommended Taxotere for advanced ...
UPDATE 1-EU panel rejects bowel drug, backs shingles shot Mar 24, 2006
Reuters AGN.N: Quote, Profile, Research) Ganfort eye-drop solution and backed the use of Sanofi-Aventis SA's (SASY.PA: Quote, Profile, Research) Taxotere in advanced ...
Paris shares close up after Alcatel merger news boosts tech stocks ... Mar 24, 2006
Forbes Sanofi-Aventis finished up 0.30 eur or 0.39 pct at 78.45, after saying a committee of the EU's European Medicines Agency has recommended Taxotere for advanced ...
Panel ends hopes for Novartis bowel drug in Europe Mar 24, 2006
Reuters ...supported the use of Allergan Inc's (AGN.N: Quote, Profile, Research) Ganfort eye-drop solution and backed the use of Sanofi-Aventis's Taxotere in advanced ...
European Indexes Climb Mar 24, 2006
BusinessWeek The operating margin of 12.7% was above its initial target of 12%. Sanofi got US FDA approval for its Taxotere drug in the treatment of stomach cancer. ...
(PRN) - Medical Services Obtains Positive Results in 2006 ... [+] Mar 23, 2006
Bolsamania.com, ...in New Version ... [+. PRN) - TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach Cancer ... [+. PRN) - On Command ...
Abraxis Oncology Names Joseph Hogan Vice President of US Sales and ... Mar 20, 2006
Finanzen.net, For more information, visit APP's websiteat www.appdrugs.com and www.abraxisoncology.com. Taxotere(R) is a registered trademark of Aventis Pharmaceuticals,Inc.
Oncologists Jumped Gun on Taxanes After Oral Presentation Mar 17, 2006
MedPage Today, The increase in the number of patients getting taxanes -- either Taxol or Taxotere (docetaxel) -- was steady at about 0.15% a month (with a 95% confidence ...
GPC Biotech Presents New Satraplatin Clinical Data From ... Feb 27, 2006
PR Newswire (press release), New Preclinical Data on Efficacy of Satraplatin in Prostate Cancer Cells And With Taxotere(R) Also Presented MARTINSRIED/MUNICH, Germany, Feb. ...
Cytogen's Quadramet Helps Lower PSA Feb 27, 2006
Houston Chronicle, In a mid-stage study, the use of Quadramet combined with Sanofi-Aventis SA's Taxotere was shown to lower levels of prostate specific antigen, or PSA, by more ...
Matrix Metalloproteinase Inhibitor Effective for Kaposi’s ... Mar 22, 2006
Cancer Consultants (press release), ...than doxorubicin. Both Taxotere® (docetaxel) and Taxol® have significant activity in recurrent Kaposi’s sarcoma. Matrix metalloproteinases ...
GPC Biotech Presents New Satraplatin Clinical Data From ... Feb 27, 2006
Yahoo! News (press release) Seven patients in the study had hormone-refractory prostate cancer (HRPC), and all of the HRPC patients had received Taxotere® (docetaxel), with a median of ...
Sanofi-Aventis' Battered Charm Mar 1, 2006
BusinessWeek Key brands, such as Plavix, Taxotere and Eloxatin oncology treatments, Lantus antidiabetes agent, and Avapro -- an antihypertensive -- will likely drive the ...
Cell Genesys gives promising prostate cancer trial update Feb 28, 2006
Pharmaceutical Business Review ...median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Sanofi-Aventis' Taxotere (docetaxel) chemotherapy plus ...
Progen Half Yearly Financial Results Mar 15, 2006
PharmaLive.com (press release), Progress was also made in the ongoing Phase II clinical trial of PI-88 and Taxotere in advanced lung cancer with 95 patients recruited to date. ...
Genta Incorporated Announces Fourth Quarter and Year End 2005 ... Mar 10, 2006
PR Newswire (press release), Most recently, Mr. Sanders was Vice-President, Oncology Sales, at sanofi-aventis, where he led the Eloxatin(R), Taxotere(R), and ELITEK(R) sales teams. ...
Latest In Prostate Cancer Therapy Presented At A New Style ... Mar 9, 2006
Medical News Today (press release), On the other side, when cancer becomes life-threatening, we have recent evidence that the new chemotherapy, using bisphosphonates and taxotere, may prolong ...
GPC says satraplatin well tolerated in Phase I Feb 27, 2006
Reuters It said of the 17 patients, seven had hormone refractory prostate cancer, and had received Taxotere, a chemotherapy treatment for some types of cancer ...
Positive Findings From Clinical Studies of QUADRAMET(R) in ... Feb 27, 2006
International News Service, This phase II study was designed to evaluate the tolerability and efficacy of QUADRAMET in combination with docetaxel (Taxotere(R), Aventis Pharmaceuticals, a ...
American Bioscience Inc. Names Barry Flannelly, Pharm.D, MBA, as ... 21 Dec 2005
PR Newswire (press release), ...- Former Global Brand Leader for Femara(R) at Novartis Oncology and Vice President Oncology Marketing for Taxotere(R) at Sanofi-Aventis to Lead Global Rollout ...
GPC Partners Satraplatin With Pharmion For Potential $270M 21 Dec 2005
BioWorld Online (subscription), In addition, GPC started a Phase I trial over the summer of satraplatin in combination with Taxotere (docetaxel) in advanced solid tumors. ...
Taxotere® Vs. Taxol® in Adjuvant Treatment of Breast Cancer Dec 14, 2005
Cancer Consultants (press release), Taxotere® (docetaxel) and Taxol® (paclitaxel) produce similar outcomes when given after Adriamycin® (doxorubicin) and Cytoxan® (cyclophosphamide) in the ...
Interim Analysis of Phase 3 Study Shows Taxotere (docetaxel)-Based ... Dec 16, 2005
DG News ...first interim efficacy and updated safety analyses from the BCIRG 006 phase 3 breast cancer study, which show that Herceptin(R) combined with Taxotere(R)-based ...
Taxotere® and Taxol® Produce Same Results Following AC in ... Dec 15, 2005
Cancer Consultants (press release), ...the Cancer and Acute Leukemia Group G (CALGB) and the North Central Cancer Treatment Group (NCCTG) recently reported results that both Taxotere (docetaxel) and ...
Taxotere®/Cytoxan® Superior to Standard Adriamycin®/Cytoxan as ... Dec 14, 2005
Cancer Consultants (press release), Researchers from the US Oncology Research in Houston reported that the chemotherapy combination Taxotere (docetaxel) plus Cytoxan (cyclophosphamide) provides ...
Sanofi-Aventis says phase III Taxotere study shows significant ... Dec 8, 2005
Forbes PARIS (AFX) - Sanofi-Aventis said its Taxotere cancer therapy showed 'significantly improved disease free survival' rates in breast cancer patients during a ...
Sanofi-Aventis: Taxotere sales set for modest boost Dec 5, 2005
Pharmaceutical Business Review 5 Dec 2005, 16:50 GMT - Having demonstrated a significant survival benefit in the treatment of advanced gastric cancer, Taxotere has been granted priority ...
Short-Course of Herceptin® Active with Taxotere® as Adjuvant ... Dec 9, 2005
Cancer Consultants (press release), Researchers from Finland reported that Taxotere (docetaxel) plus an anthracycline-based regimen in addition to a 9-week course of Herceptin appears promising ...
Interim Analysis of Phase III Study Shows TAXOTERE(R)-Based ... Dec 8, 2005
PR Newswire (press release), ...interim efficacy and updated safety analyses from the BCIRG 006 Phase III breast cancer study, which show that HERCEPTIN(R) combined with TAXOTERE(R)-based ...
SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast ... Dec 12, 2005
MedPage Today, 12 - Adjuvant chemotherapy with Taxotere (docetaxel) and Cytoxan (cyclophosphamide) delivers 33% better disease-free survival than the standard regimen of ...
Taxotere/Cyclophosphamide Offers Greater Disease-Free Survival for ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- The combination of docetaxel (Taxotere) and cyclophosphamide should replace doxorubicin (Adriamycin)/cyclophosphamide ...
Sanofi Won't Benefit From Taxotere Study Dec 9, 2005
New Ratings 0933 GMT [Dow Jones] Sanofi-Aventis's (SNY) shares won't benefit from the positive results of the Taxotere study released Thursday evening as it was already ...
Sanofi's Taxotere wins US FDA priority review for gastric cancer ... Dec 1, 2005
Forbes PARIS (AFX) - Sanofi-Aventis SA said its blockbuster cancer drug Taxotere has received a 6-month priority review by the US Food and Drug Administration for a ...
Sanofi Wins Review for New Taxotere Application Dec 2, 2005
Reuters ...said on Friday the US Food and Drug Administration had granted a six-month priority review of a potential new application for its chemotherapy drug Taxotere. ...
FDA Grants Priority Review to Taxotere for the Supplemental New ... Dec 2, 2005
PharmaLive.com (press release), ...the US Food and Drug Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere(R) (docetaxel ...
Sanofi Taxotere Review "As Expected" Dec 2, 2005
New Ratings 0847 GMT [Dow Jones] FDA granting Sanofi-Aventis (SNY) priority review of Taxotere no surprise, says Paris-based analyst. "This is entirely as expected... ...
Researchers study breast cancer therapy Dec 15, 2005
myDNA.com, It found that adjuvant chemotherapy with the drugs Taxotere (docetaxel) and Cytoxan (cyclophosphamide) improves disease-free survival rates by 33 percent over ...
Source: sanofi-aventis Dec 8, 2005
Yahoo! News (press release) ...efficacy and updated safety analyses from the BCIRG 006 Phase III breast cancer study, which show that HERCEPTIN® combined with TAXOTERE®-based regimens ...
SD Pharmaceuticals Completes Studies on the Feasibility of a Novel ... Dec 14, 2005
Genetic Engineering News, ...seven studies showed equal or superior efficacy in two different cancer models (sarcoma and liver cancer) when compared to the current Taxotere(TM) formulation ...
Living Longer With Prostate Cancer Dec 14, 2005
drkoop.com It's too late, and it'll be over.". But today, Visoky is doing just fine -- thanks to a combination of two drugs -- Taxotere and estramustine. ...
AstraZeneca's Casodex may get boost Dec 8, 2005
Science Daily (press release) In regard to hormone-refractory prostate cancer, Sanofi Aventis' Taxotere has a clear advantage because it is the only one to have demonstrated a survival ...
SABCS: No Differences Found In Taxane Treatment Results Dec 9, 2005
MedPage Today, Details of the 4,988-woman Eastern Cooperative Oncology Group E1199 study comparing Taxotere (docetaxel) and Taxol (paclitaxel) were released early at the San ...
SD Pharma encouraged by pre-clinical studies on cancer treatment Dec 14, 2005
San Diego Daily Transcript (subscription), ...(News) reported Wednesday that it has completed a battery of pre-clinical studies on its novel formulation of Docetaxel or Taxotere. ...
Bid for Aletia Hudson Dec 13, 2005
New Zealand Herald, She has had a mastectomy and started a regular chemo course, but because of the type of cancer she also needs two drugs - Taxotere and Hercepton - to greatly ...
Prostate cancer: awaiting innovation Dec 8, 2005
Pharmaceutical Business Review ...for the disease. Sanofi-Aventis’ Taxotere has emerged as the only drug to demonstrate a survival advantage in HRPC. Novacea’s ...
Application for Advanced Gastric Cancer Drug Gets FDA Priority ... Dec 2, 2005
EndoNurse, ...and Drug Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere® (docetaxel) Injection ...
Chemo regimen can limit Herceptin heart risk-study Dec 8, 2005
Reuters The 3,222 women enrolled in the trial received either standard treatment with Adriamycin and Carboplatin followed by Taxotere, an experimental regimen of ...
Breast cancer drug looks more promising Dec 8, 2005
Miami Herald, Women got one of three regimens: standard treatment with Adriamycin (an anthracycline) and carboplatin followed by Taxotere; standard treatment plus a year of ...
Herceptin Plus Chemotherapy Improves Survival in Early Breast ... Dec 8, 2005
Newswise (press release) Patients received one of three regimens: • The standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT). • An ...
Use of Herceptin and Chemotherapy Improves Survival in Early Stage ... Dec 9, 2005
Innovations-Report, Patients received one of three regimens: * The standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT). * An experimental ...
Combining herceptin with chemotherapy improves survival in breast ... Dec 11, 2005
Webindia123, Patients received one of three regimens: * The standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT). An experimental ...
Prostate Cancer: New choice for hormone refractory patients Dec 8, 2005
PharmaLive.com (press release), ...“Sanofi-Aventis’ Taxotere (docetaxel) has emerged as the only drug to demonstrate a survival advantage in hormone-refractory prostate cancer (HRPC). ...
Studies favor breast-cancer drug Dec 9, 2005
Seattle Times, ...one of three regimens: standard treatment with Adriamycin (an anthracycline also known as doxorubicin) and carboplatin followed by Taxotere; standard treatment ...
Good news, bad news in battle against breast cancer Dec 8, 2005
San Antonio Express (subscription), ...study involving 3,222 women combined Herceptin with two different chemotherapy combinations, either Adriamycin, carboplatin and Taxotere, or Taxotere and ...
Drug cocktail recipe for success Dec 9, 2005
Edmonton Journal, Just as important, the new chemo mix -- Herceptin and Taxotere -- doesn't cause the heart failure to which earlier mixes were prone. ...
Chemo 'cuts Herceptin heart risk' Dec 9, 2005
DeHavilland, The women were given one of three treatments: standard treatment with Adriamycin and carboplatin followed by Taxotere; standard treatment plus Herceptin; and ...
Herceptin OK as upfront cancer drug Dec 9, 2005
Monsters and Critics.com, In Slamon`s study, patients were treated with three different regimens: One contained Adriamycin, cyclophosphamide and docetaxel (Taxotere); the same ...
Drug ups cancer survival, heart risk Dec 9, 2005
United Press International The study found women who took Herceptin for one year after taking either Adriamycin, carboplatin and Taxotere, or Taxotere and carboplatin, had significantly ...
New research a boost for cancer drug Dec 10, 2005
Columbia Daily Tribune, Women got either standard treatment with Adriamycin (an anthracycline) and carboplatin followed by Taxotere; standard treatment plus a year of Herceptin; or a ...
Non-Anthracycline Chemotherapy Regimen Plus Herceptin®: Effective ... Dec 13, 2005
Cancer Consultants (press release), A phase III randomized trial reported that the non-anthracycline containing chemotherapy regimen of Taxotere® (docetaxel) and Paraplatin® (carboplatin ...
Chemoradiation Shrinks Pancreatic Tumors to Operable Size Dec 8, 2005
MedPage Today, The trial tested a high-dose Taxotere (docetaxel) and Gemzar (gemcitabine) combination followed by twice-weekly Gemzar and external beam radiotherapy for six ...
FDA gives Sanofi drug fast track review Dec 2, 2005
CNN/Money The Food and Drug Administration on Friday granted fast track review status to Taxotere, which is being reviewed for a supplemental use, the treatment of ...
Breast cancer drug looks more promising after further research Dec 8, 2005
KRIS-TV, ...drastically lower the cost of the pricey treatment. The study was paid for by Sanofi-Aventis, which makes Taxotere, and Genentech.
Non-Anthracycline Regimens Plus Herceptin Effective with Less ... Dec 9, 2005
Cancer Consultants (press release), ...phase III randomized trial (BCIRG 006 study) has indicated that the non-anthracycline containing chemotherapy regimen utilizing Taxotere® (docetaxel) and ...
Breast cancer drug gains support Dec 8, 2005
Kansas.com, Women got one of three regimens: standard treatment with Adriamycin and carboplatin followed by Taxotere; standard treatment plus a year of Herceptin; or a ...
I can't have drugs that will ease my agony ... they cost too much Dec 5, 2005
Glasgow Evening Times, Last month, the Scottish Medicines Consortium rejected Taxotere, approved for advanced breast cancer patients, for cost reasons. ...
FDA Grants Priority Review for Sanofi Cancer Drug Dec 2, 2005
Business New Jersey (subscription), ...cancer. Sanofi said the FDA has granted a priority review for the drug Taxotere in combination with chemotherapy treatment cisplatin. ...
Favrille Announces Appointment of David Guy as Chief Commercial ... Dec 5, 2005
PharmaLive.com (press release), ...specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin(R), Fludara(R) and Taxotere(R)," said Dr ...
Active Biotech Reports Interim Results of ANYARA Phase I Clinical ... Dec 14, 2005
Market Wire (press release) A parallel trial, investigating the drug in combination with Taxotere®, is running concurrently at clinics in the USA, Denmark and Russia. ...
NHS Lothian has seen its costs rise 10% in the past year Dec 1, 2005
Scotsman, And the prostate cancer drug Taxotere, which can extend life and significantly reduce pain, is not considered good value at £6000 per treatment. ...
Bioxel Pharma Broadens its Taxane Product Line Nov 18, 2005
CCNMatthews (press release), Docetaxel is the active pharmaceutical ingredient manufactured by Sanofi-Aventis and marketed under the trade name Taxotere ® . ...
(PRN) New Study Demonstrates Nonanthracycline Adjuvant Regimen TC ... Dec 11, 2005
Houston Chronicle, He explained that researchers designed a trial to test the efficacy of the nonanthracycline -based regimen of TC, marketed as Taxotere by sanofi aventis ... |
